11 Results for "

hypoxia-activated

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "hypoxia-activated" in MCE Product Catalog:

8
8 Cited Publications
Cat. No.: HY-10535
CAS No.: 918633-87-1
Purity:  ≥98.0%
Synonyms: TH-302
Target:  

Apoptosis

Research Areas:  

Cancer

Evofosfamide (TH-302) is a hypoxia-activated proagent with IC50 of 10 μM and 1000 μM in hypoxia (N2) and normoxia (21% O2), respectively.
loading...
    loading...
Cat. No.: HY-124098
CAS No.: 2903-45-9
Purity:  99.92%
Synonyms: Lidocaine N-oxide
Research Areas:  

Cardiovascular Disease

Lignocaine N-oxide (Lidocaine N-oxide) is a hypoxia-activated prodrug of lidocaine (HY-B0185). Lignocaine N-oxide exerts exactly the same sodium current-blocking effect as lidocaine only when it is converted to lidocaine under ischemic conditions. Lignocaine N-oxide possesses antiarrhythmic activity against ischemia-induced ventricular fibrillation. Lignocaine N-oxide can be used in studies related to ischemia-induced ventricular fibrillation .
loading...
    loading...
Cat. No.: HY-16405
CAS No.: 851627-62-8
Research Areas:  

Cancer

PR-104 is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104, as a nitrogen mustard pre-proagent, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A .
loading...
    loading...
Cat. No.: HY-161838
Target:  

ATM/ATR

Research Areas:  

Cancer

ICT10336 is a hypoxia-responsive prodrug of ATR inhibitor, AZD6738 (HY-19323). ICT10336 is hypoxia-activated and specifically releases AZD6738 only in hypoxic conditions in vitro. This can inhibit ATR activation (T1989 and S428 phosphorylation) and subsequently abrogate HIF1a-mediated adaptation of hypoxic cancers cells, thus selectively inducing cell death in 2D and 3D cancer models. ICT10336 is a metabolic substrate of CYPOR activity.
loading...
    loading...
Cat. No.: HY-16406
CAS No.: 851627-80-0
Research Areas:  

Cancer

PR-104 (sodium) is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104 (sodium), as a nitrogen mustard pre-proagent, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A .
loading...
    loading...
Cat. No.: HY-139701
CAS No.: 2733559-66-3
Target:  

HDAC

Research Areas:  

Cancer

NI-Pano (CH-03) is a novel hypoxia-activated KDAC inhibitor. NI-Pano (CH-03) is reduced in an O2-dependent manner to release panobinostat.
loading...
    loading...
Cat. No.: HY-170565
CAS No.: 3041166-70-2
Target:  

Mitophagy Apoptosis

Research Areas:  

Cancer

CHD-1 is a a hypoxia-activated antitumor prodrug. CHD-1 impairs mitochondrial morphology and membrane potential in hypoxic tumor cells, further triggering excessive mitophagy and inducing apoptosis. CHD-1 inhibits the growth of hypoxic tumor cells in vitro and the growth of HeLa xenograft in vivo .
loading...
    loading...
Cat. No.: HY-149257
CAS No.: 2973282-50-5
Target:  

JAK STAT

Research Areas:  

Cancer

HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions .
loading...
    loading...
Cat. No.: HY-173256
Hyp-dBET1 is a hypoxia-activated BRD4 PROTAC degrader. The IC50 of Hyp-dBET1 for reducing cell viability under hypoxic conditions is approximately 153 nM to 192 nM, while it shows low activity under normoxic conditions (IC50 of approximately 2.8 μM to 3.8 μM). Hyp-dBET1 induces BRD4 degradation under hypoxic conditions, converts to dBET1 in hypoxic environments, and downregulates the expression level of ZFP-91. Hyp-dBET1 can be used in studies related to breast cancer, cervical cancer and solid tumors .
loading...
    loading...
Cat. No.: HY-170774
Hypoxia inducer-1 (Compound N6) is an orally active hypoxia activated nitric oxide (NO) donor compound. Hypoxia inducer-1 exhibits highly selective NO release under hypoxic conditions and inhibits hypoxia-induced apoptosis, necrosis, and the increase in ROS levels. Hypoxia inducer-1 regulates vascular dilation and has a protective effect in a mouse model of myocardial hypoxia injury. Hypoxia inducer-1 can be used in the research of coronary heart disease .
loading...
    loading...
Cat. No.: HY-10535R
CAS No.: 918633-87-1
Synonyms: TH-302 (Standard)
Research Areas:  

Cancer

Evofosfamide (Standard) is the analytical standard of Evofosfamide (HY-10535). This product is intended for research and analytical applications. Evofosfamide (TH-302) is a hypoxia-activated proagent with IC50 of 10 μM and 1000 μM in hypoxia (N2) and normoxia (21% O2), respectively.
loading...
    loading...
  • 1